358 related articles for article (PubMed ID: 31275327)
1. Circulating Myeloid Derived Suppressor Cells (MDSC) That Accumulate in Premalignancy Share Phenotypic and Functional Characteristics With MDSC in Cancer.
Ma P; Beatty PL; McKolanis J; Brand R; Schoen RE; Finn OJ
Front Immunol; 2019; 10():1401. PubMed ID: 31275327
[TBL] [Abstract][Full Text] [Related]
2. CD200 promotes immunosuppression in the pancreatic tumor microenvironment.
Choueiry F; Torok M; Shakya R; Agrawal K; Deems A; Benner B; Hinton A; Shaffer J; Blaser BW; Noonan AM; Williams TM; Dillhoff M; Conwell DL; Hart PA; Cruz-Monserrate Z; Bai XF; Carson WE; Mace TA
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581043
[TBL] [Abstract][Full Text] [Related]
3. Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment.
Ostrand-Rosenberg S; Fenselau C
J Immunol; 2018 Jan; 200(2):422-431. PubMed ID: 29311384
[TBL] [Abstract][Full Text] [Related]
4. Plasticity of myeloid-derived suppressor cells in cancer.
Tcyganov E; Mastio J; Chen E; Gabrilovich DI
Curr Opin Immunol; 2018 Apr; 51():76-82. PubMed ID: 29547768
[TBL] [Abstract][Full Text] [Related]
5. Myeloid-Derived Suppressor Cells Specifically Suppress IFN-γ Production and Antitumor Cytotoxic Activity of Vδ2 T Cells.
Sacchi A; Tumino N; Sabatini A; Cimini E; Casetti R; Bordoni V; Grassi G; Agrati C
Front Immunol; 2018; 9():1271. PubMed ID: 29928279
[TBL] [Abstract][Full Text] [Related]
6. Circulating myeloid-derived suppressor cells: An independent prognostic factor in patients with breast cancer.
Safarzadeh E; Hashemzadeh S; Duijf PHG; Mansoori B; Khaze V; Mohammadi A; Kazemi T; Yousefi M; Asadi M; Mohammadi H; Babaie F; Baradaran B
J Cell Physiol; 2019 Apr; 234(4):3515-3525. PubMed ID: 30362521
[TBL] [Abstract][Full Text] [Related]
7. Polymorphonuclear Myeloid-Derived Suppressor Cells Are Abundant in Peripheral Blood of Cancer Patients and Suppress Natural Killer Cell Anti-Tumor Activity.
Tumino N; Besi F; Martini S; Di Pace AL; Munari E; Quatrini L; Pelosi A; Fiore PF; Fiscon G; Paci P; Scordamaglia F; Covesnon MG; Bogina G; Mingari MC; Moretta L; Vacca P
Front Immunol; 2021; 12():803014. PubMed ID: 35116033
[TBL] [Abstract][Full Text] [Related]
8. Tumour-activated liver stromal cells regulate myeloid-derived suppressor cells accumulation in the liver.
Zhang H; He G; Kong Y; Chen Y; Wang B; Sun X; Jia B; Xie X; Wang X; Chen D; Wei L; Zhang M; Zeng H; Chen H
Clin Exp Immunol; 2017 Apr; 188(1):96-108. PubMed ID: 28019655
[TBL] [Abstract][Full Text] [Related]
9. How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions.
Bruger AM; Dorhoi A; Esendagli G; Barczyk-Kahlert K; van der Bruggen P; Lipoldova M; Perecko T; Santibanez J; Saraiva M; Van Ginderachter JA; Brandau S
Cancer Immunol Immunother; 2019 Apr; 68(4):631-644. PubMed ID: 29785656
[TBL] [Abstract][Full Text] [Related]
10. Systemic but not MDSC-specific IRF4 deficiency promotes an immunosuppressed tumor microenvironment in a murine pancreatic cancer model.
Metzger P; Kirchleitner SV; Boehmer DFR; Hörth C; Eisele A; Ormanns S; Gunzer M; Lech M; Lauber K; Endres S; Duewell P; Schnurr M; König LM
Cancer Immunol Immunother; 2020 Oct; 69(10):2101-2112. PubMed ID: 32448983
[TBL] [Abstract][Full Text] [Related]
11. Myeloid-derived suppressor cells in lymphoma: The good, the bad and the ugly.
Betsch A; Rutgeerts O; Fevery S; Sprangers B; Verhoef G; Dierickx D; Beckers M
Blood Rev; 2018 Nov; 32(6):490-498. PubMed ID: 29691090
[TBL] [Abstract][Full Text] [Related]
12. Myeloid derived-suppressor cells: their role in cancer and obesity.
Ostrand-Rosenberg S
Curr Opin Immunol; 2018 Apr; 51():68-75. PubMed ID: 29544121
[TBL] [Abstract][Full Text] [Related]
13. Immunophenotyping of Circulating Myeloid-Derived Suppressor Cells (MDSC) in the Peripheral Blood of Cancer Patients.
Bruderek K; Schirrmann R; Brandau S
Methods Mol Biol; 2021; 2236():1-7. PubMed ID: 33237535
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models.
Greene S; Robbins Y; Mydlarz WK; Huynh AP; Schmitt NC; Friedman J; Horn LA; Palena C; Schlom J; Maeda DY; Zebala JA; Clavijo PE; Allen C
Clin Cancer Res; 2020 Mar; 26(6):1420-1431. PubMed ID: 31848188
[TBL] [Abstract][Full Text] [Related]
15. Characterization of a whole blood assay for quantifying myeloid-derived suppressor cells.
Apodaca MC; Wright AE; Riggins AM; Harris WP; Yeung RS; Yu L; Morishima C
J Immunother Cancer; 2019 Aug; 7(1):230. PubMed ID: 31462270
[TBL] [Abstract][Full Text] [Related]
16. Expansion and functions of myeloid-derived suppressor cells in the tumor microenvironment.
Qu P; Wang LZ; Lin PC
Cancer Lett; 2016 Sep; 380(1):253-6. PubMed ID: 26519756
[TBL] [Abstract][Full Text] [Related]
17. Myeloid Derived Suppressor Cells: Key Drivers of Immunosuppression in Ovarian Cancer.
Baert T; Vankerckhoven A; Riva M; Van Hoylandt A; Thirion G; Holger G; Mathivet T; Vergote I; Coosemans A
Front Immunol; 2019; 10():1273. PubMed ID: 31214202
[TBL] [Abstract][Full Text] [Related]
18. TLR8 ligation induces apoptosis of monocytic myeloid-derived suppressor cells.
Dang Y; Rutnam ZJ; Dietsch G; Lu H; Yang Y; Hershberg R; Disis ML
J Leukoc Biol; 2018 Jan; 103(1):157-164. PubMed ID: 29345064
[TBL] [Abstract][Full Text] [Related]
19. Importance of myeloid derived suppressor cells in cancer from a biomarker perspective.
Kalathil SG; Thanavala Y
Cell Immunol; 2021 Mar; 361():104280. PubMed ID: 33445053
[TBL] [Abstract][Full Text] [Related]
20. Asah2 Represses the p53-Hmox1 Axis to Protect Myeloid-Derived Suppressor Cells from Ferroptosis.
Zhu H; Klement JD; Lu C; Redd PS; Yang D; Smith AD; Poschel DB; Zou J; Liu D; Wang PG; Ostrov D; Coant N; Hannun YA; Colby AH; Grinstaff MW; Liu K
J Immunol; 2021 Mar; 206(6):1395-1404. PubMed ID: 33547170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
